Back to search

France· FR:62350477

DEXAMETHASONE KRKA 4 mg/ml, solution injectable/pour perfusion

A medicinal product containing phosphate sodique de dexaméthasone, registered in France by KRKA (SLOVENIE).

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedDEXAMETHASONE KRKA 4 mg/ml, solution …ATC—REGISTER NO.FR:62350477PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PHOSPHATE SODIQUE DE DEXAMÉTHASONE
Manufacturer
KRKA (SLOVENIE)
Country
France (FR)
ATC code
—
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930204368
    20 ampoule(s) en verre jaune(brun) suremballée(s)/surpochée(s) PVC-Aluminium de 1 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Phosphate sodique de dexaméthasone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All phosphate sodique de dexaméthasone products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Dexamethason Hcs, Dexamethason Kalceks
  • Belgium · Darazon, Dexalis
  • Bulgaria · Dexanova, Дeксаметазон Крка
  • Cyprus · Axium-Opto, Decadron
  • Czechia · Dexamed, Dexamethasone Fmk
  • Germany · Dexa, Dexa Edo
  • Denmark · Axiumopto, Dexacur
  • Estonia · Caltrixan, Dexamethason Krka
  • Spain · Amexxine, Dexafree
  • Finland · Axiumopto, Dexacur
  • United Kingdom (Northern Ireland) · Dexafree, Dexamethason Glenmark Pharmaceuticals Europe
  • Greece · Amelinor, Axium
  • Croatia · Darazur, Deksametazon Kalceks
  • Hungary · Darazur, Dexamethasone Kalceks
  • Ireland · Dexafree, Dexamethasone Activase Pharmaceuticals
  • Iceland · Dexametason Abcur, Dexamethason Krka
  • Italy · Amexzur, Cortmuper
  • Liechtenstein · Neofordex, Ozurdex
  • Lithuania · Dexamethason Krka, Dexamethasone Kalceks
  • Luxembourg · Dexalis, Dexamethasone Kalceks
  • Latvia · Dexamethason Krka, Dexamethasone Kalceks
  • Malta · Axium-Opto, Decadron
  • Netherlands · Axium-Opto, Dexamethason
  • Norway · Dexacur, Dexametason Abcur
  • Poland · Covexan, Darazur
  • Portugal · Amexzur, Decadron
  • Romania · Dexametazonă Fosfat Krka, Dexametazona Krka
  • Sweden · Axiumopto, Baxil
  • Slovenia · Deksametazon Krka, Deksametazon Medochemie
  • Slovakia · Amexxine, Dexametazón Krka

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b13c1a99-2372-4f69-b01c-833b4d05a4e7
GET /v1/drugs/b13c1a99-2372-4f69-b01c-833b4d05a4e7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "62350477",
  "date_amm": "2020-04-30",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "PHOSPHATE SODIQUE DE DEXAMÉTHASONE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable ou pour perfusion",
  "voies_administration": "infiltration;intraarticulaire;intralésionnelle;intramusculaire;intraveineuse;sous-conjonctivale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about phosphate sodique de dexaméthasone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.